POAI Reports Strong Results From Its AI Cancer Drug Evaluation
January 13 2022 - 8:30AM
Predictive Oncology Inc. (NASDAQ: POAI) reported the preliminary
results of its Discovery 2021 program today, announcing that its
Helomics subsidiary’s evaluation demonstrated their proprietary
Artificial Intelligence (AI) program CoRE™ (Computational Research
Engine), combined with their tumor profile data and matched ovarian
cancer samples, could identify potential new chemotherapy drug
uses. These drugs are not currently approved for ovarian cancer,
but, with further study, could be used for ovarian cancer treatment
following clinical trial and regulatory approval.
The Discovery 2021 program has combined Helomics’ proprietary
knowledgebase, its AI Machine Learning Program and its TruTumor™
platform to create PeDAL™ (Patient-centric Discovery by Active
Learning). PeDAL is a unique approach to drug discovery,
accelerating the selection process to identify potential lead
compounds for use in all cancers, not just ovarian. POAI is ready
to partner with biopharmaceutical companies.
Active learning-driven experimentation iteratively improves a
predictive model until it reaches a specific desired goal.
Helomics’ evaluation demonstrated that PeDAL made confident
predictions for at least 9 times the number of drug-cancer sample
combinations studied while identifying potential drugs for
repurposing in ovarian cancer treatment. “The study constructed a
model of the effects of 175 cancer drugs on 130 patient tumor cell
lines. The results indicate that after measuring only 2.6% of all
combinations of drugs and cell lines, high confidence predictions
could be made for an additional 24% of the combinations,” said Dr.
Robert F. Murphy, Professor of Computational Biology
Emeritus at Carnegie Mellon University and co-inventor of CoRE
and a member of Predictive Oncology’s Scientific Advisory Board.
PeDAL predicted drugs to inhibit cancer in up to 40% of the samples
in the study. In addition, variation was observed in the
effectiveness of different drugs with the same identified mechanism
of action.
“PeDAL leads to a better selection of drugs, matching the
different cancer types to the patients associated with those
cancers and potential treatments, improving the scientific and
clinical success of drug development. This also translates to
millions of dollars in reduced development costs for our future
partners. PeDAL can now deliver a proven system that efficiently
drives drug response experiments and pulls patient-centric data
into the discovery process,” said J. Melville (Mel) Engle, CEO,
Chairman of Predictive Oncology Inc.
About Predictive Oncology
Inc.
Predictive Oncology Inc. (NASDAQ: POAI) is a knowledge-driven
company focused on applying artificial intelligence (AI) to develop
personalized cancer therapies, which can lead to more effective
treatments and improved patient outcomes. Using artificial
intelligence, Predictive Oncology uses a database of 150,000+
cancer tumors, categorized by patient type, against drug compounds
to determine optimal therapies to be used to ultimately eliminate
cancer. As the drug discovery community has now realized, a
genomics-based approach to cancer research and drug development is
insufficient to achieve the promise of personalized therapeutics.
Predictive Oncology instead takes a multiomic approach, which
considers the vast multitude of factors that make each cancer
unique.
Forward-Looking Statements: Certain matters discussed in this
release contain forward-looking statements. These forward-looking
statements reflect our current expectations and projections about
future events and are subject to substantial risks, uncertainties
and assumptions about our operations and the investments we make.
All statements, other than statements of historical facts, included
in this press release regarding our strategy, future operations,
future financial position, future revenue and financial
performance, projected costs, prospects, plans and objectives of
management are forward-looking statements. The words “anticipate,”
“believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “would,”
“target” and similar expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. Our actual future
performance may materially differ from that contemplated by the
forward-looking statements as a result of a variety of factors
including, among other things, risks that we will not be successful
in entering into partnerships with biopharmaceutical companies,
risks that the results of future evaluations of PeDAL will not be
as favorable as the preliminary results of our internal evaluation,
risks related to the recent acquisition of zPREDICTA, including no
assurance of future operating results of zPREDICTA, no assurance
that zPREDICTA’s customers will continue to utilize zPREDICTA’s
services at historical levels or at all, risk of higher than
anticipated expenses, integration risk, risk of future impairment
of goodwill that would impact POAI’s operating results and reliance
on zPREDICTA’s management and employees, and the factors discussed
under the heading “Risk Factors” in our filings with the SEC.
Except as expressly required by law, the Company disclaims any
intent or obligation to update these forward-looking
statements.
Investor Relations Contact:Landon Capital Keith
Pinder (404) 995-6671kpinder@landoncapital.net
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Apr 2023 to Apr 2024